Review

Cell-Free DNA Methylation Profiling Analysis—Technologies and Bioinformatics

Jinyong Huang and Liang Wang *

Department of Tumor Biology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA; Jinyong.huang@moffitt.org
* Correspondence: liang.wang@moffitt.org; Tel.: +1-813-745-4955

Received: 11 October 2019; Accepted: 4 November 2019; Published: 6 November 2019

Abstract: Analysis of circulating nucleic acids in bodily fluids, referred to as “liquid biopsies”, is rapidly gaining prominence. Studies have shown that cell-free DNA (cfDNA) has great potential in characterizing tumor status and heterogeneity, as well as the response to therapy and tumor recurrence. DNA methylation is an epigenetic modification that plays an important role in a broad range of biological processes and diseases. It is well known that aberrant DNA methylation is generalizable across various samples and occurs early during the pathogenesis of cancer. Methylation patterns of cfDNA are also consistent with their originated cells or tissues. Systemic analysis of cfDNA methylation profiles has emerged as a promising approach for cancer detection and origin determination. In this review, we will summarize the technologies for DNA methylation analysis and discuss their feasibility for liquid biopsy applications. We will also provide a brief overview of the bioinformatic approaches for analysis of DNA methylation sequencing data. Overall, this review provides informative guidance for the selection of experimental and computational methods in cfDNA methylation-based studies.

Keywords: liquid biopsies; cell-free DNA; DNA methylation; bioinformatic; next-generation sequencing

1. Introduction

Cancer is one of the leading causes of death worldwide and the total number of diagnosed cancer cases keeps increasing globally [1]. Currently, tissue biopsies are the gold standards for cancer diagnosis as well as for molecular characterization. However, these conventional sampling methods have shown some limitations including difficulty in obtaining sufficient biomaterial, sampling bias arising from tumor genetic heterogeneity, and even procedural complications [2]. To address these issues, liquid biopsies, which are the analyses of circulating nucleic acids in blood or other body fluids, have emerged as a critical supplement to the tissue biopsies. Compared to tissue biopsies, liquid biopsies have several obvious advantages. First, the collection of blood is minimally invasive. Second, circulating nucleic acids in blood have a short half-life between 16 minutes and 2.5 hours, allowing liquid biopsies to be real-time and dynamic monitoring tools to estimate the tumor burden [3]. Third, since circulating nucleic acids can originate from different tissues, including metastatic tumor sites, liquid biopsies may represent a whole picture of a patient’s malignancy and solve the problem of tumor heterogeneity [4,5]. Recent studies have shown that liquid biopsies have a great potential to discover novel biomarkers for cancer diagnosis and prognosis [6–8]. Therefore, liquid biopsies have attracted great attention in recent years.

Cell-free DNA (cfDNA) in body fluids is a mixture of extracellular DNA fragments that are released from cells via apoptosis, necrosis, and active secretion [9]. The length of cfDNA is about 167 bp, corresponding to the unit size of a nucleosome [10,11]. Compared to healthy controls, a significantly higher level of cfDNA in cancer patients has been reported [12]. In addition, the increased cfDNA
may decrease to the background level following surgery [13]. Results from these studies suggest that tumor-derived cfDNA is present in the blood of cancer patients. This tumor-derived cfDNA is called circulating tumor DNA (ctDNA). However, genetic analysis of ctDNA is very challenging because cfDNA is often limited in yield and highly fragmented [14]. Most importantly, ctDNA is extremely underrepresented in the high background of normal cfDNA [14]. The increasing availability and reliability of highly sensitive technologies, such as droplet digital PCR (ddPCR) and next-generation sequencing (NGS), are facilitating the development of liquid biopsies [15]. Currently, detections of cancer-related hotspot mutations have been approved for clinical applications. However, due to the limited number of recurrent mutations available for discriminating ctDNA from total cfDNA, application of these hot-spot detections is very limited [16,17]. On the other hand, aberrant DNA methylation occurs early during tumorigenesis and is abundantly present in the entire cancer process [18]. Therefore, it is believed that analysis of the ctDNA methylation pattern may be a more robust and sensitive approach for cancer diagnosis and prognosis [19].

DNA methylation is a common epigenetic modification achieved by adding a methyl group to the fifth carbon of cytosine (5-methylcytosine, 5mC) via DNA methyltransferases (DNMTs) (Figure 1). This modification occurs most frequently at cytosine residues in the sequence context of 5'-C-phosphate-G-3' (CpG) [20]. The current human genome build contains about 28 million CpGs, 60–80% of which are methylated [21]. Generally, the majority of all CpGs are methylated in human, except short unmethylated regions called CpG islands (CGIs) [22]. On the contrary, the cancer genome is characterized by global hypomethylation and CGI-specific hypermethylation, resulting in genomic instability and transcriptional repression, respectively [23,24]. Growing evidence suggests that aberrant DNA methylation contributes to the tumorigenesis and tumor progression, which enables DNA methylation analysis as a promising approach for cancer detection [25–28]. Interestingly, the methylation patterns of cfDNA are consistent with the cells or tissues where they originate [29], implying that cfDNA methylation may serve as feasible and reliable cancer biomarkers [30,31].

**Figure 1.** Cytosine variants and their products by bisulfite conversion. DNA methyltransferases (DNMTs) convert unmodified cytosine (C) to 5-methylcytosine (5mC) by adding a methyl group. Ten-eleven translocation (TET) enzymes oxidize 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Thymine DNA glycosylase (TDG) and the base excision repair (BER) pathway allow for regeneration of C from 5fC and 5caC. Upon bisulfite treatment, unmethylated cytosine (C) is deaminated to uracil (U) and eventually converted to thymine (T) via DNA amplification, while methylated C remains unaffected. 5hmC also protects C from deamination, while 5fC and 5caC do not.

## 2. Technologies for DNA Methylation Detection

### 2.1. Restriction Enzyme-Based Methods

The use of methylation restriction enzymes (MREs) to cleave DNA at a specific nucleotide sequence is a classical method for methylation study. Generally, two kinds of enzymes are used in this method. Methylation-sensitive enzymes cleave only unmethylated DNA and leave the methylated DNA intact, while methylation-insensitive enzymes can cleave regardless the methylation status of the recognition

---

**Cancers 2019, 11, 1741**

---

2 of 22
sites (see Reference [32] for all available MREs). Base on this principle, many array hybridization methods have been developed for detecting 5mC. For example, the HpaII-tiny fragment Enrichment by Ligation-mediated PCR (HELP) assay [33] and methyl-sensitive cut counting (MSCC) [34]. More recently, MRE digestion followed by sequencing (MRE-seq or methyl-seq) has been developed and used to study the role of DNA methylation in regulating alternative promoters [35,36]. After digestion, the fragmented DNA is directly sized-selected for library preparation without the need for sonication. However, due to the limited CpG-containing recognition sites, MRE-seq exhibits a lack of coverage of the whole methylome. Importantly, the severely fragmented nature of cfDNA restricts the application of MRE-seq for cfDNA methylation profiling as some restriction sites may have been destroyed. With the emergence of ddPCR, absolute quantification of DNA methylation based on MRE digestion has been developed [37]. Briefly, MRE is used to recognize methylated and unmethylated DNA. Then the methylation level is determined quantitatively on the microfluidic chip using Poisson statistics. Due to high sensitivity of ddPCR, this method allows ultra-low DNA input and therefore suitable for target-specific liquid biopsies. Moreover, it allows for a relatively easy primer and probe design as it is free from bisulfite conversion.

2.2. Bisulfite Conversion-Based Methods

Bisulfite conversion-based methods are regarded as the gold standard for DNA methylation study. Upon sodium bisulfite treatment on denatured DNA, unmethylated cytosine (C) residues are deaminated to uracil (U) and eventually converted to thymine (T) via DNA amplification, while methylated C residues remain unaffected (Figure 1) [38]. Analysis of bisulfite-converted DNA was previously coupled with Sanger sequencing to investigate specific DNA sequences. Nowadays, NGS allows for genome-wide methylation study, where DNA methylation sites in a single-base resolution can be detected. However, bisulfite conversion causes substantial DNA degradation [39], which may result in loss of some critical information, especially when cfDNA input is typically low. Therefore, the library preparation and treatment process should be optimized for high-quality bisulfite sequencing.

2.2.1. Whole-Genome Bisulfite Sequencing (WGBS)

WGBS presents the most comprehensive and informative DNA methylation profiling technology [40], which was first developed to map the human DNA methylomes [41]. The major advantage of WGBS is that the methylation state of every cytosine, including low CpG density regions and non-CpG sites (CpA, CpT, and CpC), can be detected. However, since the whole genome is targeted, the cost of WGBS is extremely high when producing high depth data. To apply WGBS for liquid biopsies, end repair and methylated adapter ligation at both ends of cfDNA fragments are performed before bisulfite treatment as it ensures amplification after bisulfite treatment (Figure 2) [42]. To address increasing demand for the analysis of low input DNA, optional methods such as single-cell bisulfite sequencing (scBS-seq) [43] and single-cell whole-genome bisulfite sequencing (scWGBS) [44] have also been developed. scBS-seq adopts a post-bisulfite adapter tagging protocol to reduce bisulfite-induced DNA loss and eliminate the need for global amplification [45], while scWGBS uses post-bisulfite, single-strand library preparation. WGBS has been applied for mapping cancer-associated cfDNA methylation in metastatic breast cancer (BC) [46]. However, as the cost of large-scale WGBS is prohibitive, a sample pooling approach was adopted. In the absence of individual sample analysis, a few samples may overshadow the other samples. As a result, the complexity of the pool is reduced. Fortunately, the costs of sequencing have continuously decreased in recent years, making WGBS more and more economically feasible.

2.2.2. Reduced-Representation Bisulfite Sequencing (RRBS)

To investigate DNA methylome more cost-effectively, RRBS was developed by integrating MspI digestion, bisulfite conversion, and NGS for the analysis of CpG-rich regions [47,48]. This method can detect more than 83% of CGIs in mammalian genome when the MspI-digested fragments are
size-selected between 40 and 220 bp [49]. Similar to MRE-seq, RRBS has relatively low coverage toward intergenic and distal regulatory elements because of the limited CpG-containing recognition sites. To apply this method for limited cfDNA, single-cell RRBS (scRRBS) has been developed and the input is significantly decreased. To avoid DNA loss, scRRBS integrates all the key RRBS reactions into a single-tube reaction so that DNA purification does not occur until the bisulfite conversion is completed (Figure 2). This is achieved by modifying the buffer system and the reaction volumes to preserve the activities of different enzymes [50,51]. Also, it is recommended that a gel-based approach is used in size selection step to thoroughly remove the primer dimers, which are more likely to occur when the input is low. Capitalizing on this strategy, scRRBS has been successfully used for methylation profiling of plasma cfDNA for the first time. Consequently, methylated haplotype analysis in plasma cfDNA has demonstrated the quantitative estimation of tumor load and tissue-of-origin mapping [52].

2.2.3. Methylated CpG Tandems Amplification and Sequencing (MCTA-seq)

MCTA-seq is a highly sensitive technique for detecting hypermethylated CGIs [53]. In this approach, a primer that consists of a semi-random sequence, a unique molecular identifier (UMI) sequence, and an anchor sequence is used to amplify and extend the bisulfite converted DNA at the 3’-end. Compared to unmethylated CGIs and non-CGI fragments, methylated CGIs are expected to be amplified to a higher degree because of the higher methylated CpG density. Then, the methylated CpG tandem sites are selectively amplified using another primer containing the CpG tandem sequence CGCGCGG. Only the methylated CGI sequences can be further amplified and sequenced (Figure 2). This approach preferentially enriches CGIs and allows as little as 7.5 pg cfDNA input through multiple rounds of amplification. However, as MCTA-seq can only detect CpG tandem regions, it will miss the non-CpG methylation. Application of the MCTA-seq in cfDNA has identified dozens of DNA hypermethylation markers for effective detection of hepatocellular carcinoma (HCC) and colorectal cancer (CRC) [53,54]. These biomarkers, including known and novel, demonstrate a high sensitivity and specificity for disease detection at an early stage.

![Figure 2. Schematic diagram of bisulfite-based cfDNA methylation profiling technologies, including whole-genome bisulfite sequencing (WGBS), reduced-representation bisulfite sequencing (RRBS), methylated CpG tandems amplification and sequencing (MCTA-seq), and targeted bisulfite sequencing.](image-url)
2.2.4. Targeted Bisulfite Sequencing

Although allowing for the discovery of novel DNA methylation alterations, the methods described above are not practical for clinical applications, where a rapid turn-around time, cost-efficient methods and high depth of sequencing coverage are required [55]. Consequently, targeted methylation sequencing is more clinically pragmatic, because it is scalable, economical, and allows for a higher depth of sequencing coverage. Depending on target enrichment manners, targeted bisulfite sequencing may be categorized into the following two groups: target amplification using PCR and target enrichment using probe hybridization (Figure 2). Specific primers can be used to amplify regions of interest after the bisulfite treatment, such as EFC#93 primers for disseminated BC [56] or Vimentin and Fibulin 1 primers for HCC [57]. Alternatively, probe sequences can be designed, synthesized, and 5’-biotinylated for target enrichment of the bisulfite converted libraries. Namely, 5’-biotinylated capture probes are used to specifically pull down DNA fragments that contain target CpG sites. This method has been used for cancer detection and classification [58]. Although targeted bisulfite sequencing has been investigated for cancer diagnostics and assessment of therapeutic outcomes, this method is constrained by the relatively complicated primer and probe design for bisulfite-converted sites.

2.2.5. Methylation Array

Illumina Infinium HumanMethylation450 BeadChip (HM450K) contains predesigned probes for more than 450k methylation sites that cover 96% of the CGIs [59] and dominated as the method of choice for the cancer methylome studies before the prevalence of NGS [60]. Infinium MethylationEPIC BeadChip, a further developed version, covers more than 850k CpG methylation sites, including almost all sites on the 450K array plus additional CpG sites in the enhancer regions [61]. Currently, a huge number of HM450K datasets on Gene Expression Omnibus (GEO) [62] and The Cancer Genome Atlas (TCGA) [63] have become an outstanding public resource for the discovery of novel DNA methylation markers [19,64] and the validation of new DNA methylation assays. As for liquid biopsies, the Infinium methylation array has been applied for the epigenome-wide discovery of non-invasive methylation biomarkers for CRC using a cfDNA pooling strategy [65]. The methylation data have also been used for the deconvolution of the plasma methylome for the inference of tissue origins of cfDNA [29]. However, all array-based methods have a drawback in poor genome-wide coverage of all methylation sites, resulting in the loss of other methylation contexts.

2.2.6. Methylation-specific PCR (MSP)

MSP is based on the use of two distinct methylation-specific primer sets for detecting the DNA of interest. The methylated primer will amplify bisulfite converted methylated DNA and untreated DNA, while the unmethylated primer is specific for bisulfite converted DNA in an unmethylated condition [66]. Taking advantage of real-time PCR, several quantitative MSP (qMSP) protocols have been developed [67–69]. Moreover, methylation-sensitive high-resolution melting analysis (MS-HRM) has been developed for methylation detection [70]. These technologies have been widely used in the identification and validation of ctDNA-specific aberrant DNA methylation [71–75]. For example, the plasma cfDNA methylation of SEPT9 has been identified as a biomarker for the noninvasive diagnosis of CRC and hepatocellular carcinoma [76,77]. With a significant advance on ddPCR, a droplet digital methylation-specific PCR (ddMSP) panel has been established for the cfDNA-based early detection of BC [78]. Also, methylation of NPY and a five-genes panel have been reported as biomarkers for metastatic CRC using ddMSP [79,80]. Yet, these individual markers only provided a limited picture of the whole tumor methylome. Therefore, a combination of multiple markers is highly recommended in a clinical setting to ensure a high sensitivity and specificity.
2.3. Enrichment-based methods

The strategy for enrichment-based methods is to use anti-methylcytosine antibodies or methyl-CpG binding proteins to pull-down the methylated genomic regions for subsequent analysis, while the unmethylated fractions are excluded by stringent washing. Compared to WGBS methods, these enrichment-based methods have not only shown a similar sensitivity and slightly better specificity [81] but also many other advantages. They are cost-effective because only the enriched fragments are sequenced so many more indexed samples can be pooled simultaneously for NGS. Furthermore, the enrichment approach does not involve cytosine conversion and can discriminate 5mC from 5-hydroxymethylcytosine (5hmC) due to the protein-binding specificity. However, these methods have a relatively low resolution of ≈100–300 bp, and therefore may not discriminate the exact methylation context. Additionally, these methods tend to exhibit biases toward hypermethylated regions. As the standard protocol of these methods require relatively large amount of DNA input, further optimization for the library preparation and methylation enrichment is needed for cfDNA-based studies. It is necessary to be aware that missing signal can mean an unmethylated sequence or an uncaptured sequence due to low input.

2.3.1. Methylated DNA Immunoprecipitation Sequencing (MeDIP-seq)

MeDIP was originally developed as an approach for the immunoprecipitation of methylated DNA followed by a microarray analysis [82]. A low DNA input protocol has been reported to reduce the required input from 5000 ng to 50 ng DNA. However, using less than 50 ng DNA as an input was not recommended due to insufficient methylation enrichment [83]. To apply MeDIP-seq for low-input cfDNA in liquid biopsies, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) has been developed, where exogenous lambda DNA is used as a filler to increase the initial DNA input (Figure 3) [84]. The filler DNA ensures a constant antibody/DNA ratio and helps maintain a similar immunoprecipitation efficiency across different samples with different cfDNA yields, while minimizing non-specific binding and DNA loss [85]. With the help of filler DNA, the starting cfDNA can be reduced to ≈1-10 ng. Because the lambda DNA does not have sequencing adapters, and hence no subsequent amplification, the use of filler DNA would not interfere with the analysis of sequencing data. An application of the cfMeDIP-seq in a group of lung cancer patients and controls has identified a set of significant differentially methylated genes [86]. However, the sample size (n = 3) was too small and a large dataset is needed to validate the finding.

2.3.2. Methyl-CpG Binding Domain Protein Capture Sequencing (MBD-seq)

Instead of immunoprecipitation, the methyl-CpG binding domain (MBD) of methyl-CpG binding proteins (MBD2 or MECP2) can be used to pull down methylated DNA fragments with the help of magnetic beads [87]. It has been shown that MBD-based enrichment outperforms MeDIP in regions with a higher CpG density and identifies the greatest proportion of CGIs [88]. Therefore, integrating MBD-seq with liquid biopsies may facilitate the discovery of ctDNA hypermethylation signatures. A study has described a low DNA input MBD-seq protocol by adjusting the DNA to beads ratio and using more incubation time and more stringent wash conditions [89]. Using this protocol, MBD-seq with a 15 ng DNA input detected 93% of the methylated loci that were reliably detected using WGBS (sensitivity) at similar levels of the false positive rate (specificity). Even with as little as 5 ng DNA, MBD-seq had a 90% of sensitivity and equal levels of specificity relative to WGBS [89]. Therefore, this low-input technology is suitable for liquid biopsy studies. Also, it is expected that the use of exogenous DNA as a filler to increase the initial input might increase the capture efficiency for MBD proteins as it does for immunoprecipitation.
2.4. 5-hydroxymethylation profiling

Ten-eleven translocation (TET) enzymes can oxidize 5mC to 5hmC, 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), which is known as DNA demethylation (Figure 1) [90, 91]. Emerging evidence indicates that 5hmC not only acts as a relatively stable epigenetic marker in mammals [92] but also correlates with tumorigenesis and tumor progression [93]. Previously, studies have shown the reduced global 5hmC levels but increased regional 5hmC levels in various cancer tissues [94]. These observations suggest that 5hmC signatures may also be promising biomarkers for cancer diagnostics and prognostics. Due to the low frequency of 5hmC, however, the detection of 5hmC is technically more challenging. Also, bisulfite sequencing does not distinguish between 5mC and 5hmC because both are resistant to bisulfite treatment [95]. Hence, bisulfite-free 5hmC profiling methods have been developed.

2.4.1. 5hmC-Seal (aka hMe-Seal)

In 5hmC-Seal, an azide-modified glucose is first introduced by β-glucosyltransferase (β-GT) and subsequently biotinylated via click chemistry in selective chemical labeling (Figure 3) [96]. The biotinylated 5hmC is then enriched using streptavidin beads followed by NGS to determine the genomic distribution of 5hmC, where spike-in probes are adopted to test the 5hmC capture efficiency during the 5hmC-Seal assay. As 5hmC-Seal can work with ultra-low levels of starting DNA (~5 ng) [94], this technology has been applied for liquid biopsies, where cfDNA was first ligated with sequencing adapters. The proof-of-principle global analysis of hydroxymethylome in cfDNA has been reported [97]. Since then, the 5hmC-Seal has been used to identify a genome-wide pattern of cancer-associated 5hmC changes and tissue origins of such changes in plasma cfDNA from a patient-derived xenograft mouse model [98]. The method has also been used to detect large-scale aberrant 5hmC alternations in both gene bodies and promoter regions for non-small-cell Lung Cancer (NSCLC) [99], CRC [100], HCC [101],
and esophageal cancer [102]. Because the total read count is used in predefined genomic regions to estimate 5hmC level, the resolution of 5hmC-Seal is relatively low.

2.4.2. hmC-CATCH

To solve the problem of low resolution, hmC-CATCH, a bisulfite-free method for the genome-wide detection of 5hmC, has been reported recently, where the single-base resolution hydroxymethylome in human has been revealed for the first time [103]. This method is based on the principle of blocking 5fC, selective oxidation of 5hmC to 5fC, chemical labeling of the newly generated 5fC, and a subsequent C-to-T transition during PCR amplification (Figure 3). Because the endogenous 5fC is first blocked and only the newly generated 5fC are detected, this technology is specific for 5hmC. To test hmC-CATCH for liquid biopsies, 5hmC enrichment profiles in cfDNA using both hmC-CATCH and 5hmC-Seal have been compared and the results showed good agreement [103]. Therefore, this technology has great potential for high resolution 5hmC signature studies.

2.4.3. Hydroxymethylated DNA Immunoprecipitation Sequencing (hMeDIP-seq)

hMeDIP is modified from MeDIP and allows for specific enrichment of DNA fragments containing 5hmC [104]. This method has become an invaluable tool for determining genome-wide profiles of 5hmC. hMeDIP involves immunoselection and immunoprecipitation using anti-5hmC antibodies followed by downstream analysis such as PCR, microarray, or NGS. So far, application of hMeDIP-seq for liquid biopsies has not been reported, possibly due to the input limitation. Like cfMeDIP-seq, it is expected that application of exogenous DNA as a filler to increase the initial input may facilitate cfDNA 5hmC profiling analysis.

2.4.4. Oxidative Bisulfite Conversion

Taking advantage of the fact that cytosines in 5fC and 5caC are not protected from deamination by sodium bisulfite (Figure 1), oxidative bisulfite sequencing (OxBS-seq) [105] and TET-assisted bisulfite sequencing (TAB-seq) [106] have been developed, respectively. However, as longer bisulfite treatment and oxidative environment are needed for the efficient conversion of 5mC to 5fC or 5caC, more DNA degradation and DNA damage may occur [107]. Application of these methods in liquid biopsies need further investigation.

3. Bioinformatics Analysis of Sequencing-Based DNA Methylation Data

The general workflow for the bioinformatics analysis of DNA methylation sequencing data includes quality assessment of reads (FastQC [108]), adapter trimming (Trimmomatic [109], Trim Galore [110]), read alignments to a reference genome, post-alignment quality control, data visualization (UCSC Genome Browser [111], Integrative Genomics Viewer (IGV) [112], Methylation plotter [113], and Web Service for Bisulfite Sequencing Data Analysis (WBSA) [114]), quantification of the DNA methylation level or genomic coverage, and identification of differentially methylated cytosines (DMCs) or differentially methylated regions (DMRs) (Figure 4) [115,116]. Here, we will provide the analysis strategies for DNA methylation sequencing data. All these strategies are highly compatible when cfDNA is used as a starting material.

3.1. Alignment and Quality Controls

Standard aligners are not available for bisulfite sequencing data because the bisulfite converted DNA does not align to the reference genome. To address this issue, two algorithms have been developed for the alignment of bisulfite sequencing data: wild card algorithm (GSNAP [117]) and three-letter algorithm (Bismark [118], BS Seeker 2 [119,120]). The wild card algorithm allows both Cs and Ts in reads to map into Cs in the reference genome, while the three-letter algorithm converts all Cs in the reference genome and the reads into Ts, and thus standard aligners can be adopted [121].
Post-alignment quality control is important for bisulfite sequencing data to reliably quantify read counts and the methylation level per base. For example, base-calling quality should be checked because miscalled bases can be counted as C-T conversions. Since the end repair step in library preparation may introduce either methylated or unmethylated Cs [115], low quality bases on sequence ends should be trimmed to minimize false C-T conversions. It is critical to check the unique alignment rates and insert lengths after trimming because bisulfite treatment causes substantial DNA degradation. Incomplete bisulfite conversion also causes false positive results as unconverted unmethylated Cs are considered as methylated. To address this issue, spike-in sequences with unmethylated Cs are usually added to measure the bisulfite conversion rate. As the majority of CpGs with high inter-population differences contain common single nucleotide polymorphisms (SNPs) [122], filtering out known C/T SNPs is highly recommended. Additionally, removal of duplicate reads that align to the same genomic position arising from PCR bias is considerable. However, this is problematic in RRBS because by design reads start at the same position even if they are not PCR duplicates. Instead, one can remove regions with an unusually high coverage.

Differing from bisulfite-based methods, standard aligner (bowtie2 [123], BWA [124]) can be used for the alignment of enrichment-based sequencing data as no mutation is introduced during library preparation. In the cases of enrichment-based sequencing data, none of the post-alignment quality control issues mentioned above except duplicate reads, need to be considered. Duplicate reads are increasingly likely to occur because reads are expected to align to a smaller methylation-enriched genome, while some duplicate reads occur by chance owing to the methylation enrichment, not the PCR over-amplification. Poisson statistic has been used to determine the maximal number of duplicate reads allowed per genomic position [125].

### 3.2. DNA Methylation Calling

After a series of quality control, the methylation level of each CpG site can be calculated in the bisulfite sequencing data, which is a number ranging from 0 to 1. This is simply done by counting the number of C-T conversions and dividing the number of Cs by the sum of Cs and Ts for each C. As relative ratio, the methylation level would normalize the coverage difference at each individual CpG site, which vary dramatically due to genomic feature and amplification differences. Also, the methylation level can be easily fit into many commonly used statistics models as it is a continuous variable. However, the methylation level calculated from the CpG site with a low sequencing depth is
less reliable [126]. Alternatively, analysis on the read counts or CpG coverage data may be considered, which means directly analyzing the number of methylated and unmethylated Cs at each CpG site.

Unlike bisulfite sequencing data, data from enrichment-based methods are usually analyzed by comparing the relative abundance of fragments. Generally, the genome is divided into non-overlapped adjacent windows of a specified width and the number of read counts in each window across all samples can be used for further analysis. For analysis involving multiple samples, data normalization is crucial to remove biases between samples or different batches. Reads per kilobase million (RPKM) is a popular choice as it rescales read counts to correct for differences in both the library size and fragment length [127]. The trimmed mean of M-values (TMM) [128] and DESeq [129] calculate a scaling factor via different algorithms. Then read counts are normalized by using these scaling factors. The genomic binning function and both rpk and TMM normalization are implemented in the R package MEDIPS [125], while DESeq normalization is implemented in the R package DESeq2. More recently, a Bayesian statistical model that transforms the methylation enrichment read counts to absolute methylation levels has been developed and is implemented in the R package QSEA [130,131]. Additionally, a non-parametric method that uses isolated CpGs to estimate sample-specific fragment size distributions for the estimation of the CpG coverage of each CpG site has also been developed and is implemented in the R package RAMWAS [132,133].

### 3.3. Determination of Differential Methylation

Following methylation calling, statistical tests can be employed to identify differential methylation between cases and controls. Differential methylation in cancer means CpG sites or regions that have different DNA methylation patterns between cancer patients and healthy individuals. For a comparative analysis of the methylation level on a CpG site or region between multiple samples, standard statistical methods such as t-test, ANOVA, nonparametric test (Mann–Whitney U test and Kruskal–Wallis test), and beta regression may be used. Considering the distribution of methylation level among the study population is unknown, a nonparametric test is more preferentially adopted in methylation studies (R package BSmooth [134] and limma [135]). ANOVA is based on linear models and allows for a multiple-group comparison (R package Minfi [136]). Thus, it is more suitable in a clinical setting as it allows for the incorporation of covariates. For read counts analysis, Fisher’s exact (or chi-square) test, cluster data analysis [137], logistic regression [138], and the beta-binomial model [139–141] may be used. Fisher’s exact test is the method of choice when replicates are not available, however, it does not take the biological variability of methylation into consideration due to the pooling analysis. Regression methods also allow adding covariates, such as age and sex into the tests, which are shown to be influential on the methylation level [142]. Among these models, the beta-binomial model is the best method for balanced sensitivity and specificity in DMC detection [126].

As the methylation level between neighboring CpG sites are potentially positively correlated, a combination of multiple adjacent CpG sites into a defined region called DMR can reduce the number of hypothesis tests and thereby improve the statistical power [115]. DMRs can be determined by clustering nearby CpGs or DMCs, or by applying segmentation methods to segment the differential CpGs into hyper/hypo-methylated regions [143]. DMRs can also be defined based on predefined regions, such as gene promoters and CpG islands, or adjacent CpG sites within user-defined non-overlapped windows across the whole genome [144]. To better measure weak methylation differences, increasing the biological replicates and sequencing depth present a good strategy to obtain more robust p-values. The inherent limitation of high dimensional data is false positive. Therefore, statistical results must be subjected to multiple testing corrections. Among all options, Bonferroni and false discovery rate (FDR) are the most commonly used. Comprehensive evaluation of almost all tools and statistical methods for identifying DMRs for DNA methylation sequencing data has been summarized [126,145–149]. After the calling of DMRs, the regions of interest often need to be integrated with genome annotation datasets, which allows for determining whether the DMRs are related to genes and gene regulatory regions. The R package Genomation [150] and ChIPpeakAnno [151] are good annotation tools to be recommended.
3.4. Identification of Tumor-Specific Methylation Profile

Due to the high background of normal cells-derived cfDNA, the ctDNA concentration in cfDNA is generally low in cancer patients. Therefore, it is challenging to identify ctDNA methylation, especially in early-stage cancer. One common strategy is to use the methylation profile of tumor-free peripheral blood mononuclear cells (PBMCs) as a negative control. By comparing DMRs between cancer cfDNA and healthy cfDNA to those between cancer cfDNA and PBMC genomic DNA, the shared regions are considered to be tumor-specific DMRs. This strategy has been applied in many studies that identified the ctDNA methylation signatures \[19,84,97,98\]. Additionally, a reference-based deconvolution algorithm has been developed for correcting cell-type heterogeneity for studying methylation [152]. This algorithm allows for the recovery of the original signal from a mixture of signal sources by using reference datasets. Therefore, it is suitable for the deconvolution of data from heterogeneous samples, including cfDNA, when tissue-specific and cancer-specific methylation data are available. The deconvolution algorithm has been successfully applied to estimate ctDNA content and differentiate tissue-of-origin in cfDNA of patients with lung or colorectal cancer [52]. Recently, probabilistic models have been formulated to identify ctDNA methylation. CancerLocator, a tool for non-invasive cancer diagnosis and tissue-of-origin prediction, is based on such a model [153]. By using Infinium HM450K data from TCGA, CancerLocator identified many CpG cluster features that have significant methylation variation across cancer and normal samples, as well as modeled methylation levels in different cancer types. Thus, the ctDNA burden and the likelihood of the presence of a specific cancer type can be inferred based on the methylation data of informative CpG clusters. A further developed version, CancerDetector, adopts the joint methylation states of multiple adjacent CpG sites on an individual sequencing read and jointly deconvolutes the tumor fraction across all markers, has achieved a high sensitivity and specificity in detecting ctDNA methylation [154]. The Bayesian hierarchical model and methylation haplotype analysis share a similar strategy that enables information sharing across a cluster of neighboring CpG sites in order to enhance the statistical power [52,130,139].

4. Current Challenges and Future Directions

In the early years of development, whole blood (buffy coat) DNA was preferentially used as a starting material. However, the high background of the hematopoietic cell genome may cause a false positive detection of cfDNA-specific DMRs. Later, plasma was proven to be a superior source of cfDNA owing to the lower background levels of wild-type DNA [155]. Although superior, the combination of limiting cfDNA fragments and low ctDNA fraction in a typical early-stage cancer plasma sample still restrict the detection of methylation signatures. One should be aware that if a certain region of DNA is not present in the sample, no target enrichment technique can retrieve it. Given the extremely low ctDNA content, each sample is expected to contain a low copy number of tumor genome equivalents. Therefore, the regions with a low sequencing coverage should be considered as a potential tumor signal, rather than filtering out as low quality reads. Unfortunately, most analytical pipelines do not take such a scenario into consideration and remove low-coverage regions as part of routine quality control. This may sound reasonable for recurrence detection in an advanced stage cancer, in which tumor burden is high. However, it is obviously improper for early stage cancer since the tumor burden is extremely low.

The use of NGS in epigenetic studies has significantly facilitated our discovery of DNA methylation biomarkers. However, these studies also face some challenges, including the lack of a uniform pipeline for both experimental and computational methods. Thus, different laboratories may generate different set of biomarkers from the same type of disease or the same set of samples, and in some cases, different interpretations for the same datasets. To eliminate the inconsistency arising from tumor heterogeneity and distinctive analytical methodologies, integration of different assays and multiple biomarkers may be considered as a strategy of choice. It is believed that the combination of various methylation assays will ensure the generation of more reliable biomarkers or novel assays. For example, the high sensitivity of cfMeDIP-seq for low DNA input has been validated by comparing the results with
traditional MeDIP-seq, RRBS, and WGBS [84]. Additionally, the combination of multiple methylation markers will help to achieve a higher analytical performance. For instance, the recent assays for the early detection of BC and monitoring of treatment response in CRC used multiple methylation signatures to improve outcome [78,80]. Furthermore, the integration of cfDNA methylation analysis with other aberrant cfDNA alterations assays, such as copy number variations and point mutations, may also improve the diagnostic sensitivity and specificity.

Although promising, the integrated strategy will produce more complicated data, which requires a more sophisticated analytical algorithm. With the rapid development of new computational technologies, the use of machine learning for diagnostic and therapeutic decision-making is receiving more popularity. For example, artificial intelligence systems have been adopted for methylation analysis in recent studies [84,156,157]. It is expected that machine learning will allow for the identification of trends and cancer-specific patterns with ease. However, machine learning has many obstacles. First, it requires massive training data sets. For a cancer diagnosis, more cohort information, such as sex, age, cancer type and stage, as well as diverse environmental factors (sample collection and storage), are necessary. Second, labeling and annotating the training data is a time-consuming process. Furthermore, computer program skills are also required for scientists to comprehensively analyze and interpret the vast amount of data. Therefore, significant effort is still needed to fully realize clinical application of cfDNA methylation markers in the cancer detection and outcome prediction.

Besides cfDNA methylation, other epigenetic biomarkers have also been explored for liquid biopsies. With the rapid development of cell sorting technologies, investigation of the methylome in circulating tumor cells (CTCs) has become possible [158]. A fundamental connection between phenotypic features of CTCs and DNA methylation dynamics in stemness and metastasis has been identified recently [159]. More knowledge regarding the CTC methylome remains to be further explored. Meanwhile, cell-free RNA methylation and cfDNA fragmentation patterns also deserve more research attentions in the future [160,161].

5. Conclusions

This review discussed the feasibility of current DNA methylation profiling methods in liquid biopsy applications and how technical issues are addressed by improvements in technology. We summarized the advantages and disadvantages of each technique in Table 1 as guidance toward selecting the experimental method that best fits the research topic. Whole-genome methylation profiling methods are more suitable for lab research, such as discovery of novel biomarkers, while targeted and locus-specific methods are more applicable for clinical settings. Currently, most cfDNA methylation studies are based on bisulfite conversion, while enrichment-based methods and the 5hmC profiling of cfDNA are beginning to show their potential. However, these approaches may result in the loss of key methylation information since bisulfite treatment causes substantial DNA degradation and methylation enrichment recovers only a small fraction of the total DNA input. Hence, integrating different methylation profiling assays will provide complementary information and minimize the risk of missing significant signatures, ensuring generation of more reliable biomarkers. Also, joint analysis of multiple cancer methylation signatures is believed as a promising strategy for improving the diagnostic outcome. This review also provided a brief overview of methylation sequencing data analysis. Currently, most liquid biopsy studies adopted the same methods as tissue-based data analysis, while the deconvolution of data from heterogeneous cfDNA is gaining more attention. The invention of novel analysis methodologies that allow for the discrimination of ctDNA methylation signal is clearly needed. Future applications will be facilitated using artificial intelligence and machine-learning algorithms to identify clinically meaningful patterns in the data. Particular attention should be paid to ameliorate the cfDNA extraction procedures for high quality cfDNA, optimizing library preparation and methylation treatment methods for low input cfDNA, increasing the sequencing depth for accurate methylation calculations, and exploiting analytical methodologies for ctDNA-specific methylation detection.
Table 1. Strengths and weaknesses of all major methylation assays for liquid biopsies

| Class                     | Technology          | Strength                                           | Weakness                                                                 | Cost  |
|---------------------------|---------------------|----------------------------------------------------|--------------------------------------------------------------------------|-------|
| Restriction enzyme-based  | qPCR or ddPCR       | -High CGI coverage                                 | -Low resolution                                                         | Low   |
|                           |                     | -Allows ultra-low DNA input                        | -Limited to regions in proximity to restriction enzyme sites            |       |
|                           |                     | -Easy primer design                                | -Loci-specific studies only                                             |       |
| Bisulfite-based           | WGBS                | -Single-based resolution                           | -Substantial DNA degradation during bisulfite treatment                | High  |
|                           | RRBS                | -The most comprehensive profiling of the whole methylome | -Relatively low sequencing depth                                      |       |
|                           | MTCA-seq            | -High CGIs coverage                                | -Limited to regions in proximity to restriction enzyme sites            | Moderate |
|                           | Targeted            | -Detect target CpG sites at high coverage          | -Limited to CGIs and might decrease other methylation backgrounds    | Moderate |
|                           | Microarray          | -Pre-designed panel covering hotspot methylation  | -Complicated primer or probe design                                     | Low   |
|                           | qMSP or ddMSP       | -Allows ultra-low DNA input                        | -Low genome-wide coverage of CpGs                                     | Low   |
|                           |                     |                                                    | -Loci-specific studies only                                            |       |
|                           |                     |                                                    | -Complicated primer or probe design                                     |       |
| Enrichment-based          | MeDIP-seq           | -No mutation introduced                            | -Low resolution                                                         | Moderate |
|                           |                     | -Antibody is specific to 5mC                       | -Biased toward hypermethylated regions                                 |       |
|                           |                     |                                                    | -Less sensitive in regions with high CpG density than MBD-seq           |       |
| 5hmC profiling            | 5hmC-Seal           | -Specific to 5hmC                                  | -High sequencing depth is required as 5hmC has a low abundance         | Moderate |
|                           | hmC-CATCH           | -Ensures accurate capture of DNA containing 5hmC   | -Low resolution                                                         | Moderate |
|                           |                     | -Single-based resolution                           | -Oxidative environment would cause DNA damage                          |       |

**Abbreviations**: CGI: CpG island. CpG: 5′-C-phosphate-G-3′. qPCR: Quantitative polymerase chain reaction. ddPCR: Droplet digital polymerase chain reaction. qMSP: Quantitative methylation-specific PCR. ddMSP: Droplet digital methylation-specific PCR. MBD: Methyl-CpG binding domain.
Author Contributions: Conceptualization, L.W.; Writing—original draft preparation, J.H.; Writing—review and editing, J.H and L.W.; Supervision, L.W.; funding acquisition, L.W.

Funding: This research was supported in part by National Institute of Health (R01CA212097) and by H. Lee Moffitt Cancer Center & Research Institute.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]

2. Wan, J.C.M.; Massie, C.; Garcia-Corbacho, J.; Mouliere, F.; Brenton, J.D.; Caldas, C.; Pacey, S.; Baird, R.; Rosenfeld, N. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat. Rev. Cancer 2017, 17, 223–238. [CrossRef] [PubMed]

3. Diehl, F.; Schmidt, K.; Choti, M.A.; Romans, K.; Goodman, S.; Li, M.; Thornton, K.; Agrawal, N.; Sokoll, L.; Szabo, S.A.; et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14, 985–990. [CrossRef] [PubMed]

4. Jamal-Hanjani, M.; Wilson, G.A.; Horswell, S.; Saliari, O.; Constantin, T.; Salari, R.; Kirkizlar, E.; Sigurjonsson, S.; Pelham, R.; et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann. Oncol. 2018, 27, 862–867. [CrossRef]

5. Mattos-Arruda, L.; Weigelt, B.; Cortes, J.; Won, H.H.; Ng, C.K.Y.; Nuciforo, P.; Bidard, F.C.; Aura, C.; Saura, C.; Peg, V.; et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle. Ann. Oncol. 2018, 29, 2268. [CrossRef]

6. Chan, K.C.; Jiang, P.; Zheng, Y.W.; Liao, G.J.; Sun, H.; Wong, J.; Siu, S.S.; Chan, W.C.; Chan, S.L.; Chan, A.T.; et al. Cancer genome scanning in plasma: Detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 2013, 59, 211–224. [CrossRef]

7. Crowley, E.; Di Nicolantonio, F.; Loupakis, F.; Bardelli, A. Liquid biopsy: Monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 2013, 10, 472–484. [CrossRef]

8. Siravegna, G.; Marsoni, S.; Siena, S.; Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 2017, 14, 531–548. [CrossRef]

9. Thierry, A.R.; El Messaoudi, S.; Galan, P.B.; Anker, P.; Stroun, M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016, 35, 347–376. [CrossRef]

10. Chandrananda, D.; Thorne, N.P.; Bahlo, M. High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Med. Genom. 2015, 8, 29. [CrossRef]

11. Lo, Y.M.; Chan, K.C.; Sun, H.; Chen, E.Z.; Jiang, P.; Lun, F.M.; Zheng, Y.W.; Leung, T.Y.; Lau, T.K.; Cantor, C.R.; et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci. Transl. Med. 2010, 2, 61ra91. [CrossRef] [PubMed]

12. Schwarzenbach, H.; Hoon, D.S.; Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11, 426–437. [CrossRef] [PubMed]

13. Catario, R.; Ferreira, M.M.; Rodrigues, H.; Coelho, A.; Nogal, A.; Sousa, A.; Medeiros, R. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 2008, 27, 415–421. [CrossRef] [PubMed]

14. Spichiger, S.; Rolet, F.; Mouliere, F.; Thierry, A.R. Circulating cell-free DNA: Preanalytical considerations. Clin. Chim. Acta 2013, 424, 222–230. [CrossRef] [PubMed]

15. Diaz, L.A., Jr.; Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA. J. Clin. Oncol. 2014, 32, 579–586. [CrossRef] [PubMed]

16. Janku, F.; Huang, H.J.; Claes, B.; Falchook, G.S.; Fu, S.; Hong, D.; Ramzanali, N.M.; Nitti, G.; Cabril, G.; Timberidou, A.M.; et al. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol. Cancer Ther. 2016, 15, 1397–1404. [CrossRef] [PubMed]
17. Janku, F.; Huang, H.J.; Fujii, T.; Shelton, D.N.; Madwani, K.; Fu, S.; Tsimeridou, A.M.; Piha-Paul, S.A.; Wheler, J.J.; Zinner, R.G.; et al. Multiplex KRASG12G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. *Ann. Oncol.* 2017, 28, 642–650. [CrossRef]

18. Baylin, S.B.; Esteller, M.; Rountree, M.R.; Bachman, K.E.; Schuebel, K.; Herman, J.G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. *Hum. Mol. Genet.* 2001, 10, 687–692. [CrossRef] [PubMed]

19. Vrba, L.; Futscher, B.W. A suite of DNA methylation markers that can detect most common human cancers. *Epigenetics* 2018, 13, 61–72. [CrossRef]

20. Jones, P.A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. *Nat. Rev. Genet.* 2012, 13, 484–492. [CrossRef]

21. Smith, Z.D.; Meissner, A. DNA methylation: Roles in mammalian development. *Nat. Rev. Genet.* 2013, 14, 204–220. [CrossRef] [PubMed]

22. Suzuki, M.M.; Bird, A. DNA methylation landscapes: Provocative insights from epigenomics. *Nat. Rev. Genet.* 2008, 9, 465–476. [CrossRef] [PubMed]

23. Esteller, M. Epigenetics in cancer. *N. Engl. J. Med.* 2008, 358, 1148–1159. [CrossRef] [PubMed]

24. Baylin, S.B.; Jones, P.A. A decade of exploring the cancer epigenome - biological and translational implications. *Nat. Rev. Cancer* 2011, 11, 726–734. [CrossRef] [PubMed]

25. Koch, A.; Joosten, S.C.; Feng, Z.; de Ruiter, T.C.; Draht, M.X.; Melotte, V.; Smits, K.M.; Veeck, J.; Herman, J.G.; van Neste, L.; et al. Analysis of DNA methylation in cancer: Location revisited. *Nat. Rev. Clin. Oncol.* 2018, 15, 459–466. [CrossRef]

26. Laird, P.W. The power and the promise of DNA methylation markers. *Nat. Rev. Cancer* 2003, 3, 253–266. [CrossRef]

27. Takeshima, H.; Ushijima, T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. *NPJ Precis. Oncol.* 2019, 3, 7. [CrossRef]

28. Widschwendter, M.; Jones, A.; Evans, I.; Reisel, D.; Dillner, J.; Sundstrom, K.; Steyerberg, E.W.; Vergouwe, Y.; Wegwarth, O.; Rebitschek, F.G.; et al. Epigenome-based cancer risk prediction: Rationale, opportunities and challenges. *Nat. Rev. Clin. Oncol.* 2018, 15, 292–309. [CrossRef]

29. Moss, J.; Magenheim, J.; Neiman, D.; Zemmour, H.; Loyfer, N.; Korach, A.; Samet, Y.; Maoz, M.; Druid, H.; Arner, P.; et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. *Nat. Commun.* 2018, 9, 5068. [CrossRef]

30. Board, R.E.; Knight, L.; Greystoke, A.; Blackhall, F.H.; Hughes, A.; Dive, C.; Ranson, M. DNA methylation in circulating tumour DNA as a biomarker for cancer. *Biomark. Insights* 2008, 2, 307–319. [CrossRef]

31. Feng, H.; Jin, P.; Wu, H. Disease prediction by cell-free DNA methylation. *Brief. Bioinform.* 2019, 20, 585–597. [CrossRef] [PubMed]

32. Dam-Dcm and CpG Methylation. Available online: https://www.neb.com/tools-and-resources/sele...charts/dam-dcm-and-cpg-methylation (accessed on 6 November 2019).

33. Oda, M.; Glass, J.L.; Thompson, R.F.; Mo, Y.; Olivier, E.N.; Figueroa, M.E.; Selzer, R.R.; Richmond, T.A.; Zhang, X.; Dannenberg, L.; et al. High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. *Nucleic Acids Res.* 2009, 37, 3829–3839. [CrossRef] [PubMed]

34. Ball, M.P.; Li, J.B.; Gao, Y.; Lee, J.H.; LeProust, E.M.; Park, I.H.; Xie, B.; Daley, G.Q.; Church, G.M. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. *Nat. Biotechnol.* 2009, 27, 361–368. [CrossRef] [PubMed]

35. Maunakea, A.K.; Nagarajan, R.P.; Bilenky, M.; Ballinger, T.J.; D’Souza, C.; Fousse, S.D.; Johnson, B.E.; Hong, C.; Nielsen, C.; Zhao, Y.; et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. *Nature* 2010, 466, 253–257. [CrossRef] [PubMed]

36. Brunner, A.L.; Johnson, D.S.; Kim, S.W.; Valouev, A.; Reddy, T.E.; Neff, N.F.; Anton, E.; Medina, C.; Nguyen, L.; Chiao, E.; et al. Distinct DNA methylation patterns characterize differentiated human embryonic stem cells and developing human fetal liver. *Genome Res.* 2009, 19, 1044–1056. [CrossRef]

37. Wu, Z.; Bai, Y.; Cheng, Z.; Liu, F.; Wang, P.; Yang, D.; Li, G.; Jin, Q.; Mao, H.; Zhao, J. Absolute quantification of DNA methylation using microfluidic chip-based digital PCR. *Biosens. Bioelectron.* 2017, 96, 339–344. [CrossRef]
38. Frommer, M.; McDonald, L.E.; Millar, D.S.; Collis, C.M.; Watt, F.; Grigg, G.W.; Molloy, P.L.; Paul, C.L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc. Natl. Acad. Sci. USA* 1992, 89, 1827–1831. [CrossRef]

39. Tanaka, K.; Okamoto, A. Degradation of DNA by bisulfite treatment. *Bioorg. Med. Chem. Lett.* 2007, 17, 1912–1915. [CrossRef]

40. Beck, S.; Rakyan, V.K. The methylome: Approaches for global DNA methylation profiling. *Trends Genet.* 2008, 24, 231–237. [CrossRef]

41. Lister, R.; Pelizzola, M.; Dowen, R.H.; Hawkins, R.D.; Hon, G.; Tonti-Filippini, J.; Nery, J.R.; Lee, L.; Ye, Z.; Ngo, Q.M.; et al. Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* 2009, 462, 315–322. [CrossRef]

42. Clark, S.J.; Smallwood, S.A.; Lee, H.J.; Krueger, F.; Reik, W.; Kelsey, G. Genome-wide base-resolution mapping of DNA methylation in single cells using single-cell bisulfite sequencing (scBS-seq). *Nat. Protoc.* 2017, 12, 534–547. [CrossRef] [PubMed]

43. Smallwood, S.A.; Lee, H.J.; Angermueller, C.; Krueger, F.; Saadeh, H.; Peat, J.; Andrews, S.R.; Stegle, O.; Reik, W.; Kelsey, G. Single-cell genome-wide bisulfite sequencing for assessing epigenetic heterogeneity. *Nat. Methods* 2014, 11, 817–820. [CrossRef] [PubMed]

44. Farlik, M.; Sheffield, N.C.; Nuzzo, A.; Datlinger, P.; Schonegger, A.; Klughammer, J.; Bock, C. Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics. *Cell Rep.* 2015, 10, 1386–1397. [CrossRef]

45. Miura, F.; Enomoto, Y.; Dairiki, R.; Ito, T. Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging. *Nucleic Acids Res.* 2012, 40, e136. [CrossRef] [PubMed]

46. Legendre, C.; Gooden, G.C.; Johnson, K.; Martinez, R.A.; Liang, W.S.; Salhia, B. Whole-genome bisulfite sequencing of cell-free DNA identifies signature associated with metastatic breast cancer. *Clin. Epigenet.* 2015, 7, 100. [CrossRef] [PubMed]

47. Meissner, A.; Mikkelsen, T.S.; Gu, H.; Wernig, M.; Hanna, J.; Sivachenko, A.; Zhang, X.; Bernstein, B.E.; Nusbaum, C.; Jaffe, D.B.; et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature* 2008, 454, 766–770. [CrossRef]

48. Gu, H.; Smith, Z.D.; Bock, C.; Boyle, P.; Gnirke, A.; Meissner, A. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. *Nat. Protoc.* 2011, 6, 468–481. [CrossRef] [PubMed]

49. Smith, Z.D.; Gu, H.; Bock, C.; Gnirke, A.; Meissner, A. High-throughput bisulfite sequencing in mammalian genomes. *Methods* 2009, 48, 226–232. [CrossRef]

50. Guo, H.; Zhu, P.; Wu, X.; Li, X.; Wen, L.; Tang, F. Single-cell methylome landscapes of mouse embryonic stem cells and early embryos analyzed using reduced representation bisulfite sequencing. *Genome Res.* 2013, 23, 2126–2135. [CrossRef]

51. Guo, H.; Zhu, P.; Guo, F.; Li, X.; Wu, X.; Fan, X.; Wen, L.; Tang, F. Profiling DNA methylome landscapes of mammalian cells with single-cell reduced-representation bisulfite sequencing. *Nat. Protoc.* 2015, 10, 645–659. [CrossRef]

52. Guo, S.; Diep, D.; Plongthongkum, N.; Fung, H.L.; Zhang, K.; Zhang, K. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. *Nat. Genet.* 2017, 49, 635–642. [CrossRef] [PubMed]

53. Wen, L.; Li, J.; Guo, H.; Liu, X.; Zheng, S.; Zhang, D.; Zhu, W.; Qu, J.; Guo, L.; Du, D.; et al. Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients. *Cell Res.* 2015, 25, 1376. [CrossRef] [PubMed]

54. Li, J.; Zhou, X.; Liu, X.; Ren, J.; Wang, J.; Wang, W.; Zheng, Y.; Shi, X.; Sun, T.; Li, Z.; et al. Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing. *Clin. Chem.* 2019. [CrossRef] [PubMed]

55. Samorodnitsky, E.; Datta, J.; Jewell, B.M.; Hagopian, R.; Miyata, J.; Wing, M.R.; Damodaran, S.; Lippus, J.M.; Reeser, J.W.; Bhatt, D.; et al. Comparison of custom capture for targeted next-generation DNA sequencing. *J. Mol. Diagn.* 2015, 17, 64–75. [CrossRef]

56. Widschwendter, M.; Evans, I.; Jones, A.; Ghazali, S.; Reisel, D.; Ryan, A.; Gentry-Maharaj, A.; Zikan, M.; Cibula, D.; Eichner, J.; et al. Methylation patterns in serum DNA for early identification of disseminated breast cancer. *Genome Med.* 2017, 9, 115. [CrossRef]
57. Holmila, R.; Sklias, A.; Muller, D.C.; Degli Esposti, D.; Guillourelle, P.; McKay, J.; Sangrajrang, S.; Srivatanakul, P.; Hainaut, P.; Merle, P.; et al. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatic epithelioid carcinoma. PLoS ONE 2017, 12, e0174265. [CrossRef]

58. Liu, L.; Tounj, J.M.; Jassowicz, A.F.; Vijayaraghavan, R.; Kang, H.; Zhang, R.; Kruglyak, K.M.; Huang, H.J.; Hinoue, T.; Shen, H.; et al. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann. Oncol. 2018, 29, 1445–1453. [CrossRef] [PubMed]

59. Bibikova, M.; Barnes, B.; Tsan, C.; Ho, V.; Klotzle, B.; Le, J.M.; Delano, D.; Zhang, L.; Schroth, G.P.; Gunderson, K.L.; et al. High density DNA methylation array with single CpG site resolution. Genomics 2011, 98, 288–295. [CrossRef]

60. Stirzaker, C.; Taberlay, P.C.; Statham, A.L.; Clark, S.J. Mining cancer methylomes: Prospects and challenges. Trends Genet. 2014, 30, 75–84. [CrossRef]

61. Moran, S.; Arribas, C.; Esteller, M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics 2016, 8, 389–399. [CrossRef] [PubMed]

62. Barrett, T.; Wilhite, S.E.; Ledoux, P.; Evangelista, C.; Kim, I.F.; Tomashevsky, M.; Marshall, K.A.; Phillippy, K.H.; Stirzaker, C.; Taberlay, P.C.; Statham, A.L.; Clark, S.J. Mining cancer methylomes: Prospects and challenges. Nucleic Acids Res. 2013, 41, D991–D995. [CrossRef] [PubMed]

63. The Cancer Genome Atlas. Available online: https://www.cancer.gov/tcga (accessed on 6 November 2019).

64. Hao, X.K.; Luo, H.Y.; Krawczyk, M.; Wei, W.; Wang, W.Q.; Wang, J.; Flagg, K.; Hou, J.Y.; Zhang, H.; Yi, S.H.; et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc. Natl. Acad. Sci. USA 2017, 114, 7414–7419. [CrossRef] [PubMed]

65. Gallardo-Gomez, M.; Moran, S.; Paez de la Cadena, M.; Martinez-Zorzano, V.S.; Rodriguez-Berrocal, F.J.; Rodriguez-Girondo, M.; Esteller, M.; Cubiella, J.; Bujanda, L.; Castells, A.; et al. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples. Clin. Epigenet. 2018, 10, 53. [CrossRef] [PubMed]

66. Herman, J.G.; Graff, J.R.; Myohanen, S.; Nelkin, B.D.; Baylin, S.B. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996, 93, 9821–9826. [CrossRef] [PubMed]

67. Eads, C.A.; Danenberg, K.D.; Kawakami, K.; Saltz, L.B.; Blake, C.; Shibata, D.; Danenberg, P.; Laird, P.W. MethylQuant: A high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28, E32. [CrossRef]

68. Lo, P.K.; Watanabe, H.; Cheng, P.C.; Teo, W.W.; Liang, X.; Argani, P.; Lee, J.S.; Sukumar, S. MethySYBR, a novel quantitative PCR assay for the dual analysis of DNA methylation and CpG methylation density. J. Mol. Diagn. 2009, 11, 400–414. [CrossRef]

69. Dugast-Darzacq, C.; Grange, T. MethylQuant: A real-time PCR-based method to quantify DNA methylation at single specific cytosines. Methods Mol. Biol. 2009, 507, 281–303. [CrossRef]

70. Wojdacz, T.K.; Dobrovic, A. Methylation-sensitive high resolution melting (MS-HRM): A new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007, 35, e41. [CrossRef]

71. Li, D.; Li, P.; Wu, J.; Yi, J.; Dou, Y.; Guo, Y.; Yin, Y.; Wang, D.; Ma, C.; Qiu, L. Methylation of NBPF1 as a novel marker for the detection of plasma cell-free DNA of breast cancer patients. Clin. Chim. Acta 2018, 484, 81–86. [CrossRef]

72. Eissa, M.A.L.; Lerner, L.; Abdefatalah, E.; Shankar, N.; Canner, J.K.; Hasan, N.M.; Yaghoobi, V.; Huang, B.; Kerner, Z.; Takeasui, F.; et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin. Epigenet. 2019, 11, 59. [CrossRef]

73. Giannopoulou, L.; Mastoraki, S.; Buderath, P.; Strati, A.; Pavlakis, K.; Kasimir-Bauer, S.; Lianidou, E.S. ER1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. Gynecol. Oncol. 2018, 150, 355–360. [CrossRef] [PubMed]

74. Wasenang, W.; Chaiyarit, P.; Pronguvitaya, S.; Limpaboon, T. Serum cell-free DNA methylation of OPICM and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clin. Epigenet. 2019, 11, 39. [CrossRef] [PubMed]

75. Nunes, S.P.; Moreira-Barbosa, C.; Salta, S.; Palma de Sousa, S.; Pousa, I.; Oliveira, J.; Soares, M.; Rego, L.; Dias, T.; Rodrigues, J.; et al. Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women. Cancers (Basel) 2018, 10, 357. [CrossRef] [PubMed]
76. Fu, B.; Yan, P.; Zhang, S.; Lu, Y.; Pan, L.; Tang, W.; Chen, S.; Chen, S.; Zhang, A.; Liu, W. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer. Dis. Markers 2018, 2018, 6437104. [CrossRef]

77. Oussalah, A.; Rischer, S.; Bensenane, M.; Conroy, G.; Filhine-Tresarrieu, P.; Debard, R.; Forest-Tramoy, D.; Josse, T.; Reinicke, D.; Garcia, M.; et al. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. *EBioMedicine* 2018, 30, 138–147. [CrossRef]

78. Uehiro, N.; Sato, F.; Fu, F.; Tanaka, S.; Kawashima, M.; Kawaguchi, K.; Sugimoto, M.; Saji, S.; Toi, M. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. *Breast Cancer Res.* 2016, 18, 129. [CrossRef]

79. Boeckx, N.; Op de Beeck, K.; Beyens, M.; Deschoolmeester, V.; Hermans, C.; De Clercq, P.; Garrigou, S.; Normand, C.; Monsaert, E.; Papadimitriou, K.; et al. Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients. *Clin. Colorectal Cancer* 2018, 17, e369–e379. [CrossRef]

80. Barault, L.; Amatu, A.; Siravegna, G.; Ponzetti, A.; Moran, S.; Cassingena, A.; Mussolin, B.; Falconata, C.; Binder, A.M.; Cristiano, C.; et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. *Gut* 2018, 67, 1995–2005. [CrossRef]

81. Chan, R.F.; Shabalin, A.A.; Xie, L.Y.; Adkins, D.E.; Zhao, M.; Turecki, G.; Clark, S.L.; Aberg, K.A.; van den Oord, E. Enrichment methods provide a feasible approach to comprehensive and adequately powered investigations of the brain methylome. *Nucleic Acids Res.* 2017, 45, e97. [CrossRef]

82. Weber, M.; Davies, J.J.; Wittig, D.; Oakeley, E.J.; Haase, M.; Lam, W.L.; Schubeler, D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. *Nat. Genet.* 2005, 37, 853–862. [CrossRef]

83. Taiwo, O.; Wilson, G.A.; Morris, T.; Seisenberger, S.; Reik, W.; Pearce, D.; Beck, S.; Butcher, L.M. Methylation analysis using MeDIP-seq with low DNA concentrations. *N. Protoc.* 2012, 7, 617–636. [CrossRef] [PubMed]

84. Shen, S.Y.; Singhania, R.; Fehringr, G.; Chakravarty, A.; Roehrl, M.H.A.; Chadwick, D.; Zuzarte, P.C.; Borgida, A.; Wang, T.T.; Li, T.T.; et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. *Nature* 2018, 563, 579. [CrossRef] [PubMed]

85. Shen, S.Y.; Burgener, J.M.; Bratman, S.V.; De Carvalho, D.D. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. *Nat. Protoc.* 2019, 14, 2749–2780. [CrossRef] [PubMed]

86. Xu, W.; Lu, J.; Zhao, Q.; Wu, J.; Sun, J.; Han, B.; Zhao, X.; Kang, Y. Genome-Wide Plasma Cell-Free DNA Methylation Profiling Identifies Potential Biomarkers for Lung Cancer. *Dis. Markers* 2019, 2019, 4108474. [CrossRef] [PubMed]

87. Brinkman, A.B.; Simmer, F.; Ma, K.; Kaan, A.; Zhu, J.; Stunnenberg, H.G. Whole-genome DNA methylation profiling using MethylCap-seq. *Methods* 2010, 52, 232–236. [CrossRef]

88. Nair, S.S.; Coolen, M.W.; Stizzeker, C.; Song, J.Z.; Statham, A.L.; Strbenac, D.; Robinson, M.D.; Clark, S.J. Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. *Epigenetics* 2011, 6, 34–44. [CrossRef]

89. Aberg, K.A.; Chan, R.F.; Shabalin, A.A.; Zhao, M.; Turecki, G.; Staunstrup, N.H.; Starnawska, A.; Mors, O.; Xie, L.Y.; van den Oord, E.J. A MBD-seq protocol for large-scale methylome-wide studies with (very) low amounts of DNA. *Epigenetics* 2017, 12, 743–750. [CrossRef]

90. Tahliliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L.; et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science* 2009, 324, 930–935. [CrossRef]

91. He, Y.F.; Li, B.Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L.; et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. *Science* 2011, 333, 1303–1307. [CrossRef]

92. Bachman, M.; Uribe-Lewis, S.; Yang, X.; Williams, M.; Murrell, A.; Balasubramanian, S. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. *Nat. Chem.* 2014, 6, 1049–1055. [CrossRef]

93. Vasanthakumar, A.; Godley, L.A. 5-hydroxymethylcytosine in cancer: Significance in diagnosis and therapy. *Cancer Genet.* 2015, 208, 167–177. [CrossRef] [PubMed]
94. Han, D.; Lu, X.; Shih, A.H.; Nie, J.; You, Q.; Xu, M.M.; Melnick, A.M.; Levine, R.L.; He, C. A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. *Mol. Cell* 2016, 63, 711–719. [CrossRef] [PubMed]

95. Huang, Y.; Pastor, W.A.; Shen, Y.; Tahiliani, M.; Liu, D.R.; Rao, A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. *PLOS ONE* 2010, 5, e8888. [CrossRef] [PubMed]

96. Song, C.X.; Szulwach, K.E.; Fu, Y.; Dai, Q.; Yi, C.; Li, X.; Li, Y.; Chen, C.H.; Zhang, W.; Jian, X.; et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. *Nat. Biotechnol.* 2011, 29, 68–72. [CrossRef] [PubMed]

97. Song, C.X.; Yin, S.; Ma, L.; Wheeler, A.; Chen, Y.; Zhang, Y.; Liu, B.; Xiong, J.; Zhang, W.; Hu, J.; et al. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. *Cell Res.* 2017, 27, 1231–1242. [CrossRef] [PubMed]

98. Li, W.; Zhang, X.; Lu, X.; You, L.; Song, Y.; Luo, Z.; Zhang, J.; Nie, J.; Zheng, W.; Xu, D.; et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. *Cell Res.* 2017, 27, 1243–1257. [CrossRef] [PubMed]

99. Zhang, J.; Han, X.; Gao, C.; Xing, Y.; Qi, Z.; Liu, R.; Wang, Y.; Zhang, X.; Yang, Y.G.; Li, X.; et al. 5-Hydroxymethylome in Circulating Cell-free DNA as a Potential Biomarker for Non-small-cell Lung Cancer. *Genom. Proteom. Bioinform.* 2018, 16, 187–199. [CrossRef]

100. Gao, P.; Lin, S.; Cai, M.; Zhu, Y.; Song, Y.; Sui, Y.; Lin, J.; Liu, J.; Lu, X.; Zhong, Y.; et al. 5-Hydroxymethylcytosine profiling from genomic and cell-free DNA for colorectal cancers patients. *J. Cell Mol. Med.* 2017, 23, 1231–1242. [CrossRef] [PubMed]

101. Cai, J.; Chen, L.; Zhang, Z.; Zhang, X.; Lu, X.; Liu, W.; Shi, G.; Ge, Y.; Gao, P.; Yang, Y.; et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. *Gut* 2019. [CrossRef]

102. Tian, X.; Sun, B.; Chen, C.; Gao, C.; Zhang, J.; Lu, X.; Wang, L.; Li, X.; Xing, Y.; Liu, R.; et al. Circulating tumor DNA 5-hydroxymethylcytosine as a novel diagnostic biomarker for esophageal cancer. *Cell Res.* 2018, 28, 597–600. [CrossRef]

103. Zeng, H.; He, B.; Xia, B.; Bai, D.; Lu, X.; Cai, J.; Chen, L.; Zhou, A.; Zhu, C.; Meng, H.; et al. Bisulfite-Free, Nanoscale Analysis of 5-Hydroxymethylcytosine at Single Base Resolution. *J. Am. Chem. Soc.* 2018, 140, 13190–13194. [CrossRef] [PubMed]

104. Nestor, C.E.; Meehan, R.R. Hydroxymethylated DNA immunoprecipitation (hmeDIP). *Methods Mol. Biol.* 2014, 1094, 259–267. [CrossRef] [PubMed]

105. Booth, M.J.; Ost, T.W.; Beraldi, D.; Bell, N.M.; Branco, M.R.; Reik, W.; Balasubramanian, S. Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. *Nat. Protoc.* 2013, 8, 1841–1851. [CrossRef] [PubMed]

106. Yu, M.; Hon, G.C.; Szulwach, K.E.; Song, C.X.; Jin, P.; Ren, B.; He, C. Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine. *Nat. Protoc.* 2012, 7, 2159–2170. [CrossRef]

107. Barros-Silva, D.; Marques, C.J.; Henrique, R.; Jeronimo, C. Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications. *Genes (Basel)* 2018, 9, 429. [CrossRef]

108. FastQC. Available online: https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (accessed on 6 November 2019).

109. Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* 2014, 30, 2114–2120. [CrossRef]

110. Trim Galore. Available online: https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ (accessed on 6 November 2019).

111. Haussler, M.; Zweig, A.S.; Tyner, C.; Speir, M.L.; Rosenbloom, K.R.; Raney, B.J.; Lee, C.M.; Lee, B.T.; Hinrichs, A.S.; Gonzalez, J.N.; et al. The UCSC Genome Browser database: 2019 update. *Nucleic Acids Res.* 2019, 47, D853–D858. [CrossRef]

112. Thorvaldsdottir, H.; Robinson, J.T.; Mesirov, J.P. Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration. *Brief. Bioinform.* 2013, 14, 178–192. [CrossRef]

113. Mallona, I.; Diez-Villanueva, A.; Peinado, M.A. Methylation plotter: A web tool for dynamic visualization of DNA methylation data. *Source Code Biol. Med.* 2014, 9, 11. [CrossRef]
Cancers 2019, 11, 1741

114. Liang, F.; Tang, B.; Wang, Y.; Wang, J.; Yu, C.; Chen, X.; Zhu, J.; Yan, J.; Zhao, W.; Li, R. WBSA: Web service for bisulfite sequencing data analysis. *PLoS ONE* 2014, 9, e86707. [CrossRef] [PubMed]

115. Bock, C. Analysing and interpreting DNA methylation data. *Nat. Rev. Genet.* 2012, 13, 705–719. [CrossRef] [PubMed]

116. Langmead, B.; Salzberg, S.L. Fast gapped-read alignment with Bowtie 2.

117. Wu, T.D.; Reeder, J.; Lawrence, M.; Becker, G.; Brauer, M.J. GMAP and GSNAP for Genomic Sequence Alignment: Enhancements to Speed, Accuracy, and Functionality. *Methods Mol. Biol.* 2016, 1418, 283–334. [CrossRef] [PubMed]

118. Li, H.; Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009, 25, 1754–1760. [CrossRef] [PubMed]

119. Guo, W.; Fiziev, P.; Yan, W.; Cokus, S.; Sun, X.; Zhang, M.Q.; Chen, P.Y.; Pellegrini, M. BS-Seeker2: A versatile aligning pipeline for bisulfite sequencing data. *BMC Genom.* 2013, 14, 774. [CrossRef] [PubMed]

120. Chen, P.Y.; Cokus, S.J.; Pellegrini, M. BS Seeker: Precise mapping for bisulfite sequencing. *BMC Bioinf.* 2010, 11, 203. [CrossRef]

121. Lienhard, M.; Grimm, C.; Morkel, M.; Herrwig, R.; Chavez, L.; Tomazou, E.M.; et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. *Nucleic Acids Res.* 2014, 42, e43. [CrossRef]

122. Daca-Roszak, P.; Pfeifer, A.; Zebracka-Gala, J.; Jager, N.; Gnirke, A.; Stunnenberg, H.G.; Meissner, A. Quantitative comparison of genome-wide DNA methylation mapping technologies. *Nat. Biotechnol.* 2010, 28, 1106–1114. [CrossRef] [PubMed]

123. Wu, T.D.; Reeder, J.; Lawrence, M.; Becker, G.; Brauer, M.J. GMAP and GSNAP for Genomic Sequence Alignment: Enhancements to Speed, Accuracy, and Functionality. *Methods Mol. Biol.* 2016, 1418, 283–334. [CrossRef] [PubMed]

124. Li, H.; Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009, 25, 1754–1760. [CrossRef] [PubMed]

125. Lienhard, M.; Grimm, C.; Morkel, M.; Herrwig, R.; Chavez, L. MEDIPS: Genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments. *Bioinformatics* 2014, 30, 284–286. [CrossRef] [PubMed]

126. Zhang, Y.; Baheti, S.; Sun, Z. Statistical method evaluation for differentially methylated CpGs in base resolution next-generation DNA sequencing data. *Brief. Bioinform.* 2018, 19, 374–386. [CrossRef] [PubMed]

127. Mortazavi, A.; Williams, B.A.; McCue, K.; Schaeffer, L.; Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat. Methods* 2008, 5, 621–628. [CrossRef] [PubMed]

128. Robinson, M.D.; Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol.* 2010, 11, R25. [CrossRef] [PubMed]

129. Anders, S.; Huber, W. Differential expression analysis for sequence count data. *Genome Biol.* 2010, 11, R106. [CrossRef]

130. Down, T.A.; Rakyan, V.K.; Turner, D.J.; Flicek, P.; Li, H.; Kulesha, E.; Graf, S.; Johnson, N.; Herrero, J.; Tomazou, E.M.; et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. *Nat. Biotechnol.* 2008, 26, 779–785. [CrossRef] [PubMed]

131. Lienhard, M.; Grasse, S.; Rolf, J.; Frese, S.; Schirmer, U.; Becker, M.; Borno, S.; Timmermann, B.; Chavez, L.; Sultmann, H.; et al. QSEA-modelling of genome-wide DNA methylation from sequencing enrichment experiments. *Nucleic Acids Res.* 2017, 45, e44. [CrossRef]

132. van den Oord, E.J.; Bukszár, J.; Rudolf, G.; Nerella, S.; McClay, J.L.; Xie, L.Y.; Aberg, K.A. Estimation of CpG coverage in whole methylome next-generation sequencing studies. *BMC Bioinform.* 2013, 14, 50. [CrossRef]

133. Shabalin, A.A.; Hattab, M.W.; Clark, S.L.; Chan, R.F.; Kumar, G.; Aberg, K.A.; van den Oord, E. RaMWAS: Fast methylome-wide association study pipeline for enrichment platforms. *Bioinformatics* 2018, 34, 2283–2285. [CrossRef]

134. Hansen, K.D.; Langmead, B.; Irizarry, R.A. BSmooth: From whole genome bisulfite sequencing reads to differentially methylated regions. *Genome Biol.* 2012, 13, R83. [CrossRef]

135. Smyth, G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat. Appl. Genet. Mol. Biol.* 2004, 3. Article3. [CrossRef] [PubMed]
Cancers 2019, 11, 1741

136. Aryee, M.J.; Jaffe, A.E.; Corrada-Bravo, H.; Ladd-Acosta, C.; Feinberg, A.P.; Hansen, K.D.; Irizarry, R.A. Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics* 2014, 30, 1363–1369. [CrossRef] [PubMed]

137. Xu, H.; Podolsky, R.H.; Ryu, D.; Wang, X.; Su, S.; Shi, H.; George, V. A method to detect differentially methylated loci with next-generation sequencing. *Genet. Epidemiol.* 2013, 37, 377–382. [CrossRef] [PubMed]

138. Akalin, A.; Kormaksson, M.; Li, S.; Garrett-Bakelman, F.E.; Figueroa, M.E.; Melnick, A.; Mason, C.E. methylKit: A comprehensive R package for the analysis of genome-wide DNA methylation profiles. *Genome Biol.* 2012, 13, R87. [CrossRef] [PubMed]

139. Feng, H.; Connelly, K.N.; Wu, H. A Bayesian hierarchical model to detect differentially methylated loci from single nucleotide resolution sequencing data. *Nucleic Acids Res.* 2014, 42, e69. [CrossRef] [PubMed]

140. Park, Y.; Figueroa, M.E.; Rozek, L.S.; Sartor, M.A. methylSig: A whole genome DNA methylation analysis pipeline. *Bioinformatics* 2014, 30, 2414–2422. [CrossRef] [PubMed]

141. Dolzhenko, E.; Smith, A.D. Using beta-binomial regression for high-precision differential methylation analysis in multifactor whole-genome bisulfite sequencing experiments. *BMC Bioinform.* 2014, 15, 215. [CrossRef] [PubMed]

142. Day, K.; Waite, L.L.; Thalacker-Mercer, A.; West, A.; Bamman, M.M.; Brooks, J.D.; Myers, R.M.; Absher, D. Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. *Genome Biol.* 2013, 14, R102. [CrossRef]

143. Wreczcycka, K.; Giosdchan, A.; Yusuf, D.; Gruning, B.; Assenov, Y.; Akalin, A. Strategies for analyzing bisulfite sequencing data. *J. Biotechnol.* 2017, 261, 105–115. [CrossRef]

144. Rakyan, V.K.; Down, T.A.; Balding, D.J.; Beck, S. Epigenome-wide association studies for common human diseases. *Nat. Rev. Genet.* 2011, 12, 529–541. [CrossRef]

145. Ayyala, D.N.; Frankhouser, D.E.; Ganbat, J.O.; Marcucci, G.; Bundschuh, R.; Yan, P.; Lin, S. Statistical methods for detecting differentially methylated regions based on MethylCap-seq data. *Brief. Bioinform.* 2016, 17, 926–937. [CrossRef] [PubMed]

146. Chen, D.P.; Lin, Y.C.; Fann, C.S. Methods for identifying differentially methylated regions for sequence- and array-based data. *Brief. Funct. Genom.* 2016, 15, 485–490. [CrossRef] [PubMed]

147. Tsuji, J.; Weng, Z. Evaluation of preprocessing, mapping and postprocessing algorithms for analyzing whole genome bisulfite sequencing data. *Brief. Bioinform.* 2016, 17, 938–952. [CrossRef] [PubMed]

148. Sun, X.; Han, Y.; Zhou, L.; Chen, E.; Lu, B.; Liu, Y.; Pan, X.; Cowley, A.W., Jr.; Liang, M.; Wu, Q.; et al. A comprehensive evaluation of alignment software for reduced representation bisulfite sequencing data. *Bioinformatics* 2018, 34, 2715–2723. [CrossRef] [PubMed]

149. Yong, W.S.; Hsu, F.M.; Chen, P.Y. Profiling genome-wide DNA methylation. *Epigenet. Chromatin* 2016, 9, 26. [CrossRef]

150. Akalin, A.; Franke, V.; Vlahovicek, K.; Mason, C.E.; Schubeler, D. Genomation: A toolkit to summarize, annotate and visualize genomic intervals. *Bioinformatics* 2015, 31, 1127–1129. [CrossRef]

151. Zhu, L.J.; Gazin, C.; Lawson, N.D.; Pages, H.; Lin, S.M.; Lapointe, D.S.; Green, M.R. ChIPpeakAnno: A Bioconductor package to annotate ChIP-seq and ChIP-chip data. *BMC Bioinform.* 2010, 11, 237. [CrossRef]

152. Teschendorff, A.E.; Breeze, C.E.; Zheng, S.C.; Beck, S. A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. *BMC Bioinform.* 2017, 18, 105. [CrossRef]

153. Kang, S.; Li, Q.; Chen, Q.; Zhou, Y.; Park, S.; Lee, G.; Grimes, B.; Krysan, K.; Yu, M.; Wang, W.; et al. CancerLocator: Non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. *Genome Biol.* 2017, 18, 53. [CrossRef]

154. Li, W.; Li, Q.; Kang, S.; Same, M.; Zhou, Y.; Sun, C.; Liu, C.C.; Matsuoka, L.; Sher, L.; Wong, W.H.; et al. CancerDetector: Ultrasensitive and non-invasive cancer detection at the resolution of individual reads using cell-free DNA methylation sequencing data. *Nucleic Acids Res.* 2018, 46, e89. [CrossRef]

155. Jung, M.; Klotzke, S.; Lewandowski, M.; Fleischhacker, M.; Jung, K. Changes in concentration of DNA in serum and plasma during storage of blood samples. *Clin. Chem.* 2003, 49, 1028–1029. [CrossRef] [PubMed]

156. Panagopoulos, M.; Karaglani, M.; Balgkouranidou, I.; Biziota, E.; Koukaki, T.; Karamitroussis, E.; Nena, E.; Tsamardinos, I.; Kolios, G.; Lianidou, E.; et al. Circulating cell-free DNA in breast cancer: Size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. *Oncogene* 2019, 38, 3387–3401. [CrossRef] [PubMed]
157. Tian, Q.; Zou, J.; Tang, J.; Fang, Y.; Yu, Z.; Fan, S. MRCNN: A deep learning model for regression of genome-wide DNA methylation. *BMC Genom.* 2019, 20, 192. [CrossRef] [PubMed]

158. Pantel, K.; Alix-Panabieres, C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. *Nat. Rev. Clin. Oncol.* 2019. [CrossRef] [PubMed]

159. Gkountela, S.; Castro-Giner, F.; Szczerba, B.M.; Vetter, M.; Landin, J.; Scherrer, R.; Krol, I.; Scheidmann, M.C.; Beisel, C.; Stirnimann, C.U.; et al. Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding. *Cell* 2019, 176, 98–112.e114. [CrossRef] [PubMed]

160. Cristiano, S.; Leal, A.; Phallen, J.; Fiksel, J.; Adleff, V.; Bruhm, D.C.; Jensen, S.O.; Medina, J.E.; Hruban, C.; White, J.R.; et al. Genome-wide cell-free DNA fragmentation in patients with cancer. *Nature* 2019, 570, 385–389. [CrossRef] [PubMed]

161. Ovcharenko, A.; Rentmeister, A. Emerging approaches for detection of methylation sites in RNA. *Open Biol.* 2018, 8. [CrossRef]